The application significance of serum CYFRA21-1 change in therapeutic efficacy monitoring of advanced stage NSCLC

doi:10.3969/j.issn.1673-8640.2013.02.009

Abstract

Abstract: Objective　To investigate the significance of serum cytokeratin 19 fragment 21-1（CYFRA21-1） changes before and after chemotherapy in monitoring the therapeutic efficacy of advanced stage non small cell lung cancer（NSCLC）. Methods　The serum CYFRA21-1 levels of 66 patients with advanced stage NSCLC before and after chemotherapy and 30 healthy controls were measured by chemiluminescence immunoassay，and the change differences of serum CYFRA21-1 in the patients with different therapeutic efficacy were analyzed. Results　Compared to those in the controls，serum CYFRA21-1 levels were significantly higher than those in patients before the first-line chemotherapy（P＜0.05）. Furthermore，the serum CYFRA21-1 levels in patients with squamous cell lung carcinoma were higher than those with pulmonary adenocarcinoma（P＜0.05）. Compared to those before chemotherapy，serum CYFRA21-1 levels significantly decreased in release group after the first-line chemotherapy（P＜0.05）. However，compared to those before chemotherapy，serum CYFRA21-1 levels significantly decreased in invalid group and progress group（P＜0.05）. Conclusions　Serum CYFRA21-1 is exactly valuable in monitoring the pathogenetic condition and judging the chemotherapy efficacy of the patients with lung cancer.

Key words: Cytokeratin 19 fragment 21-1, Lung cancer, Chemotherapy, Prediction, Monitoring

ZHANG Guoming，MA Xiaobo，HU Liyi，ZANG Jialan，ZHANG Gaoming，XU Qinglei. The application significance of serum CYFRA21-1 change in therapeutic efficacy monitoring of advanced stage NSCLC[J]. , 2013, 28(2): 124-127.

References

[1]李玲，宋丽华，丁士超，等.癌胚抗原和细胞角蛋白19片段作为晚期非小细胞肺癌疗效评价指标的临床价值[J].中华肿瘤杂志，2011，32（11）：850-854.
[2]张国明，胡礼仪. 肺癌的新型标志Cytokaratin19的研究现状[J]. 牡丹江医学院学报，2011，32（3）:70-72.
[3]Ando S，Kimura H，Iwai N，et al. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer[J]. Anticancer Res，2001，21（4B）：3085-3092.
[4]Cabrera-Alarcon JL，Carrillo-Vico A，Santotoribio JD，et al. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer[J]. Clin Lab，2011，57（11-12）:1011-1014.
[5]冯晓鸿，孙业富，夏爱萍. 联合测定NSE、CYFRA21-1、PDGF-BB和D-D在肺癌患者中的临床意义[J]. 检验医学，2011，26（11）：741-745.
[6]Buccheri G，Torchio P，Ferrigno D，et al. Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer：a study of tissue polypeptide antigen and cytokeratin 19 fragments[J]. Chest，2003，124（2）:622-632.
[7]Paone G，De Angelis G，Munno R，et al. Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1[J]. Eur Respir J，1995，8（7）：1136-1140.
[8]Karnak D，Ulubay G，Kayacan O，et al. Evaluation of Cyfra21-1：a potential tumor marker for non-small cell lung carcinomas[J]. Lung，2001，179（1）:57-65.
[9]Nisman B，Biran H，Heching N，et al．Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer：association of marker changes after two chemotherapy cycles with different measures of chinical response and survival[J].Br J Cancer，2008，98（1）:77-79.
[10]Wang J，Zhang N，Li B，et al. Decline of serum CYFRA21-1 during chemoradiotherapy of NSCLC：a probable predictive factor for tumor response[J]. Tumour Biol，2011，32（4）:689-695.

[1]	ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811.
[2]	WANG Huiying, TANG Yu, DONG Lili, WANG Jing. Role of Mycoplasma pneumoniae RNA determination in diagnosis and efficacy monitoring of pneumonia in children [J]. Laboratory Medicine, 2023, 38(9): 865-869.
[3]	CHEN Ying, LI Wei, LIN Tao, YANG Li. Relationship between PFTK1 expression level and microvessel density and postoperative prognosis in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(7): 634-639.
[4]	YIN Ya, PAN Yuan, ZHOU Hongwei, SHEN Wei. Application progress of BNP and NT-proBNP in neonates [J]. Laboratory Medicine, 2023, 38(6): 518-523.
[5]	ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Roles of serum HYAL1 and HA in the auxiliary diagnosis and therapeutic monitoring of colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 313-319.
[6]	YUAN Shuang, FENG Lei, GUO Xiaofen, FU Xiaoling, XU Jing, LIU Hongyang. Relation of miR-433 in endometrial cancer tissues and its relationship with chemotherapy sensitivity [J]. Laboratory Medicine, 2023, 38(4): 337-341.
[7]	YANG Zhongxin, LI Xiaoyu, CHEN Tao, CAO Wenjun. Roles of IL-8 and MMP-2 in the prognosis of non-small cell lung cancer patients after thoracoscopic segmentectomy [J]. Laboratory Medicine, 2023, 38(4): 342-346.
[8]	SONG Shiwei, LI Jingwu, LIN Tao, LIU Zeyu, WANG Zhiqiang, SUN Weidong. Relationship between GPNMB and non-small cell lung cancer immune infiltration and prognosis [J]. Laboratory Medicine, 2023, 38(4): 347-351.
[9]	CHEN Zhe, ZHANG Ling, LIU Jie, WANG Xia, ZHANG Bin, GAO Binghua. Relationship between serum miR-326 and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy [J]. Laboratory Medicine, 2023, 38(3): 251-256.
[10]	GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206，miR-125 and miR-21 [J]. Laboratory Medicine, 2023, 38(11): 1062-1068.
[11]	WEN Jing, SHI Rui, XIE Jia, LIU Feng, LI Guang, REN Jingjing, LEI Xiaoru, GUO Xiaobo, SONG Yanping. Clinical application of metagenomic next-generation sequencing for determining pathogens in febrile neutropenic patients [J]. Laboratory Medicine, 2022, 37(9): 855-859.
[12]	LIU Xingqiang, NING Lifen, LI Lin, CHEN Zhongcheng. Correlation of lung cancer clinicopathological characteristics with FR⁺-CTC,ANXA2 and ProGRP [J]. Laboratory Medicine, 2022, 37(8): 735-740.
[13]	LIANG Chunfang, ZHU Kangning, ZHANG Qi. Serum miR-21 and miR-135a expression levels in predicting the recurrence and metastasis of gastric cancer patients after chemotherapy [J]. Laboratory Medicine, 2022, 37(5): 417-422.
[14]	GAO Feng. Research progress of new tumor molecular markers in the age of precision medicine：from accurate diagnosis to precision chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 309-312.
[15]	ZHAO Mingna, ZHANG Chenzi, HONG Qiushuang, LOU Jiatao. Mechanism of IL-8/miR-182 positive feedback regulatory axis in non-small cell lung cancer [J]. Laboratory Medicine, 2022, 37(4): 349-355.